Splenectomy with targeted therapy and immunotherapy for liver cancer
Part of Cancer clinical trials.
This trial tests whether removing the spleen (splenectomy) can improve the effectiveness of targeted therapy and immunotherapy for people with advanced liver cancer (HCC) who also have enlarged spleens due to portal hypertension. It aims to see if this combination can help control the cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 to 75 years
- No prior systemic treatment for liver cancer (or eligible for spleen removal during treatment)
- Unresectable or recurrent liver cancer (HCC)
- Enlarged spleen (>4 cm) with low white blood cell or platelet counts
- History of esophageal varices or variceal bleeding
- Liver function: Child-Pugh score 5–7, and certain blood tests within limits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy and high-precision radiation (SBRT) to shrink large or multiple liver tumors in people with hepatocellular carcinoma, with the goal of making them small enough for surgery. It's for people who cannot currently have their tumors removed but might become eligible after treatment.
This trial tests if removing the main liver tumor with surgery, followed by targeted therapy and immunotherapy, can help people with advanced liver cancer that has spread a little. It is for those who have not had prior treatment and whose liver is still working well.
This trial tests a combination of two drugs (sintilimab, an immunotherapy, and lenvatinib, a targeted therapy) followed by local treatments to try to cure advanced liver cancer that has spread to a few other parts of the body. The goal is to shrink the cancer enough that surgery or radiation can remove it completely.
This trial tests whether combining surgery to remove the main liver tumor with systemic therapy (medicines that work throughout the body) can help patients with hepatocellular carcinoma that has spread outside the liver. The goal is to improve outcomes for patients whose primary tumor can be surgically removed.
This trial tests a combination of focused radiation (SBRT), an immunotherapy drug (adelimumab), and a targeted therapy pill (apatinib) before surgery for liver cancer. The goal is to shrink tumors enough to make surgery possible or more effective.
This trial tests a combination of two drugs (lenvatinib and toripalimab, a type of immunotherapy) plus a special chemotherapy infusion directly into the liver artery for people with advanced liver cancer that has not been treated before. The goal is to see if adding the immunotherapy helps shrink tumors better than the standard combination.
Hear when a new Unresectable Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.